John Esther (@johnesthermd) 's Twitter Profile
John Esther

@johnesthermd

MD

ID: 1078753438777786368

calendar_today28-12-2018 20:43:56

7 Tweet

53 Followers

47 Following

Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Wonderful “quote” by Dr Kevin Kelly on ipilimumab nivolumab phase 2 trial in mCRPC: IF YOU CAN’T GET THE DRUG in, PATIENTS wouldn’t respond. Treatment exposure is critical. #Gu19 ASCO @GaryReedyACS

Wonderful “quote” by Dr Kevin Kelly on ipilimumab nivolumab phase 2 trial in mCRPC: IF YOU CAN’T GET THE DRUG in, PATIENTS wouldn’t respond. Treatment exposure is critical. #Gu19 <a href="/ASCO/">ASCO</a> <a href="/SKCCDirector/">@GaryReedyACS</a>
Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Breaking news 👉FDA approves 1st oral GnRHR antagonist, Relugolix @Myovant for men with advanced #prostatecancer 👏👏Great news for those with cardiovascular disease and on intermittent ADT desiring rapid testosterone recovery. OncoAlert Colloquium➡️ bit.ly/2WsQOb8

Breaking news 👉FDA approves 1st oral GnRHR antagonist, Relugolix @Myovant for men with advanced #prostatecancer 👏👏Great news for those with cardiovascular disease and on intermittent ADT desiring rapid testosterone recovery. <a href="/OncoAlert/">OncoAlert</a> Colloquium➡️ bit.ly/2WsQOb8
Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Our study in Clinical Cancer Research today: 1st report from a federally funded prospective trial (SWOG Cancer Research Network S1216) in new metastatic #prostatecancer (mCSPC)👉showing tremendous negative impact of baseline CTCs on survival outcomes👇These men need novel trials bit.ly/3ojNWst OncoAlert

Our study in <a href="/CCR_AACR/">Clinical Cancer Research</a> today: 1st report from a federally funded prospective trial (<a href="/SWOG/">SWOG Cancer Research Network</a> S1216) in new metastatic #prostatecancer (mCSPC)👉showing tremendous negative impact of baseline CTCs on survival outcomes👇These men need novel trials bit.ly/3ojNWst <a href="/OncoAlert/">OncoAlert</a>